Datapoint: GSK Scores Full Approval for Jemperli

The FDA on June 6 granted full approval to GSK’s Jemperli (dostarlimab) for the treatment of mismatch repair-deficient (dMMR) recurring or advanced endometrial cancer, in combination with chemotherapy. The agency originally granted the immune checkpoint inhibitor accelerated approval in April 2021. For the treatment of endometrial cancer, Jemperli — which is administered as an intravenous infusion — currently holds covered or better status for 88% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/7/23

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

denied-stamp
August 16

States Put Prior Authorization in Crosshairs, Even Amid Insurer Reforms

READ MORE
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 22

Datapoint: Florida Unveils Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 7

Datapoint: FDA Approves Jemperli as Frontline Endometrial Cancer Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today